[Metabolic therapy at the edge between human hosts and gut microbes].
Personalized medicine is becoming day-after-day more urgent taking into account the great diversity characterizing patients affected by a given pathology, especially metabolic diseases. In fact, antidiabetic/obesity treatments have shown a reduced or no effect at all in some patients, representing a major challenge physicians have to face worldwide. Therefore, efforts have to be put to identify individual factors affecting our susceptibility towards a given medication. In that regard, gut microbiota may stand for the missing piece of the metabolic puzzle regulating host response, since its role in the induction of metabolic diseases has now been achieved. In fact, we firstly provided a bacterial explanation for the low-grade chronic inflammation featuring metabolic diseases, by showing the lipopolysaccharide as a trigger and risk factor of such pathologies. However, despite similar lineages of microbes characterize the gut of people, important differences still remain, which may be responsible for opposite effect of treatments such as pre- or probiotics, whose efficacy seems to be governed by the own gut microbiota of subjects. We have recently shown that gut microbiota is associated to the inclination to resist or not high-fat diet-induced type 2 diabetes in mice. In addition, the direct targeting of gut microbes by dietary fibers reversed the observed metabolic phenotype. These results, together with the literature, strongly suggest gut microbiota as a new target for the development of personalized metabolic therapy.
Institut national de la santé et de la recherche médicale (Inserm), UMR 1048, Toulouse, France.
V
V
Blasco-Baque
M
M
Serino
R
R
Burcelin
D000818:Animals; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D008659:Metabolic Diseases / Q000382:microbiology* / Q000503:physiopathology / Q000628:therapy*; D051379:Mice; D057285:Precision Medicine